The options for manufacturing products using 3D screen-printing processes are extensive and varied for the life science industry. With members of the advisory board we can ensure that a transfer of expertise is guaranteed in practice and product innovations find the required added value in the application.
Prof. Riederer directed the laboratory unit of the Ludwig Boltzmann Institute for Clinical Neurobiology at Lainz Hospital, Vienna, Austria, from 1976 – 1986 and was head of the “Clinical Neurochemistry Unit” at the Department of Psychiatry, Psychosomatics and Psychotherapy at the University of Wuerzburg, Germany from 1986 – 2010.
Prof. Riederers research focus encompassed clinical research and especially basic research in the field of spectrum disorders such as depression and schizophrenia and particularly neurodegenerative disorders such as Alzheimer´s disease and Parkinson´s disease. In the latter field he is renown for his studies on MAO-Inhibitors where he initiated the use of selegiline for the treatment of PD in 1974 with the first publication in 1975. He worked in many fields of dopaminergic research like agonists and contributed to the concept of “continuous dopamine receptor stimulation”. His research resulted in the dicovery that aminoadamantanes are glutamatergic NMDA-receptor channel antagonists (1989) and his approaches in drug development focused on various aspects of effective, patient friendly drug applications (oral, sublingual, subcutaneous, etc.)
He has more than 1.100 publications in the field of Neuroscience and is Honorary member of the Austrian Parkinson´s Disease Society, the Hungarian Academy of Sciences, the German Society of Biological Psychiatry, the Austrian Alzheimer Society and the Hungarian Society of Pharmacology and Clinical Pharmacology. He is Honorary President of the German Society for Parkinson´s Disease, a member of the Deutsche Akademie der Naturforscher Leopoldina and he was the most cited chemist in the field of medicine in 2004.
He is currently Senior Professor at the University of Wuerzburg, Medical School, Germany, and holds an Adjunct Professorship at the Institute of Clinical Research at the Department of Psychiatry, Odense University Hospital, Denmark.
Prof. Riederer is President of the German Society of Clinical and Experimental Neurotherapeutics (GESENT), President of the “Verein our Durchführung neurowissenschaftlicher Tagungen e.V.” and President of the World Association for stress related and anxiety disorders (WASAD).
Prof. Rieder acts as an advisor at Laxxon Medical Ltd to the board of directors and management with his extensive expertise in the development of patient friendly drug applications for neurodegenerative disorders.
Prof. Dr. Eva Roblegg is pharmaceutical scientist at the Institute of Pharmaceutical Sciences, Deputy Head of the Department Pharmaceutical Technology and Biopharmacy at the Karl-Franzens University, Graz, Austria (http://www.uni-graz.at) and key researcher at the Research Center Pharmaceutical Engineering (http://www.rcpe.at/).
After a research visit at the Johann Wolfgang Goethe-University (Frankfurt, Germany) she finished her PhD in 2000. She took a maternity leave, spent two years in pharmacy and was approbated as pharmacist in 2005. In 2006, she joined the Institute of Pharmaceutical Sciences, Department of Pharmaceutical Technology and Biopharmacy in Graz as post-doctoral fellow and later on as Assistant Professor. In 2012 she spent 8 months as guest scientist at the Saarland University, Department Biopharmaceutics and Pharmaceutical Technology and at the Helmholtz Institute for Pharmaceutical Research Saarland, Drug Delivery Department (Saarbrücken, Germany) and was awarded with the Galenus Technology Prize 2013. She finished her habilitation in May 2014 and in 2015 and 2018 she held/holds a Guest Professorship at the University of Ljubiljana, Slovenia and at Standford University, USA.
The main focus of her research are biological barriers, in particular the oral cavity and the small intestine. In parallel, she is interested in finding oral multifunctional (nano-) drug delivery systems and developing advanced manufacturing methods such as (nano)extrusion and (nano)printing. She has (co-) supervised more than 30 diploma theses, 5 PhD students and 2 PostDocs and her publication record encompasses over 60 peer-reviewed publications and several book chapters (h-index 18). She holds two patents in the area of pharmaceutical manufacturing and has received grant support from e.g., Austrian Research Promotion Agency (FFG), EU, OECD and several industry partners.
Currently, she is Head of the Doctoral School of Pharmaceutical Sciences and Member of the Curricula Committee. Since 2009 she is also OECD Member of the Steering Group 7 for Alternative Testing Models. She serves on the editorial board of NanoTexLetters and acts as reviewer for journals such as, Nature Communications, Small, EJPB, IJP, DDIP, CLOI, Particle and Fiber Tox, Nanomedicine: Nanotechnology, Biology, and Medicine, etc..
Prof. Roblegg is an advisor at Laxxon Medical Ltd to the board of directors and management with her extensive expertise in galenics and the developing of pharmaceutical formulations for the 3D printing technology.
Dr. Christian Leist is the head of process R&D viral vectors in cell and gene therapy at Novartis Pharma Ltd in Basel. He is responsible for process development and the production (CMC development) of therapeutic active ingredients based on viral vectors for clinical test stages and market launch.
Dr. Leist has a masters degree in biology at the University of Zurich, submitted his doctoral thesis at the ETH in Zurich, where he qualified with the highest distinction in bioprocess engineering.
Dr. Leist was an assistant professor in cell culture technology at the ETH Zurich for several years before he moved to Novartis in 1989. In 2008, Dr. Leist received the Swiss Technology Award for his development of an automated analytical system (ATP Master) for real-time determination of the cellular energy charge in biotechnology processes. Dr. Leist is also a lecturer at the ETH in Zurich, very well known in the biotechnology community and has an excellent network of contacts.
Dr. Leist is an advisor at Laxxon Medical Ltd to the board of directors and management with his extensive expertise in developing opportunities in the pharmaceuticals, diagnostics and biotechnology sectors.
Dr. Marcus B Wanner has managed his own clinic for plastic surgery in Aarau since 2003 and is a member of various national and international associations and commissions.
Dr. Wanner completed his medical studies at the university in 1983 and his doctorate in 1984 on the subject of Clinical trials on granulocyte chemiluminescence in whole blood and methodical optimisation, diurnal fluctuations and activity measurements following severe burns and in the early stage following kidney transplant.
After various advances in his career, as a resident, Dr. Wanner decided in 1993 to focus on plastic and reconstructive surgery and has extended his expertise as a specialist in this field ever since. Dr. Wanner is part of an outstanding national and international network.
Dr. Wanner acts as an advisor at Laxxon Medical Ltd to the board of directors and management with his extensive expertise in the development of opportunities in the fields of medical technology and biotechnology.